TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
Rachel A. Gottschalk(Memorial Sloan Kettering Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center)
Cited by 271
Related Papers
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
|Proceedings of the National Academy of Sciences|2019|357
Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses
|The Journal of Immunology|2011|203
Attenuated T Cell Responses to a High-Potency Ligand In Vivo
|PLoS Biology|2010|112
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy
|Proceedings of the National Academy of Sciences|2024|19